Mumbai, Nov 09: Pharma Strides Pharma Science Limited today said that its step-down wholly owned subsidiary, Strides Pharma Global Pte Limited, Singapore has entered into an exclusive product development, licensing and supply agreement with SUDA Pharmaceuticals Ltd (ASX: SUD) for its novel drug SUD-001H, an oral spray of sumatriptan to treat migraine headache for the US market.
Execution of Strides' generic product pipeline for the US is nearing completion and is expected to have 150+ ANDA filings by 2021.
The company is now focusing on developing a portfolio of complex and specialty products including products filed under the 505B (2) regulatory pathway. company said in afiling with BSE.
The company through inhouse development and partnerships will build a portfolio of limited competition products offering exclusivity for a sustainable period.